Floatz logo

Therapeutic Asset Ratings

440 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Olaparib
Ovarian Cancer
Shandong UniversityP4BB (69)
Carboplatin
Ovarian Cancer
Fudan UniversityP4BB (67)
Irinotecan
Ovarian Cancer
ARCAGY/ GINECO GROUPP4BB (67)
OTL-38
Ovarian Cancer
On Target Laboratories, LLCP4BB (67)
(+)-VINCRISTINE
Ovarian Cancer
ARCAGY/ GINECO GROUPP4BB (67)
CIS-DIAMMINEDICHLOROPLATINUM II
Ovarian Cancer
Kalinski, Pawel, MD, PhDP3BB (67)
Inno-206
Ovarian Cancer
GenmabP3BB (67)
Hycamtin
Ovarian Cancer
GenmabP3BB (66)
Rivoceranib
Ovarian Cancer
Peking Union Medical College HospitalP4BB (64)
Cyclophosphamide
Ovarian Cancer
Kalinski, Pawel, MD, PhDP3BB (64)
Docetaxel
Ovarian Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P3BB (64)
FILGRASTIM
Ovarian Cancer
ARCAGY/ GINECO GROUPP3BB (64)
Catequentinib
Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP4B (63)
DEXAMETHASONE
Ovarian Cancer
Seoul National University HospitalP4B (63)
Indocyanine Green
Ovarian Cancer
Istanbul UniversityP4B (63)
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Ovarian Cancer
Sichuan Cancer Hospital and Research InstituteP4B (63)
Ifosfamide
Ovarian Cancer
Brigham and Women's HospitalP3B (63)
Tislelizumab
Ovarian Cancer
West China HospitalP3B (63)
Niraparib
Ovarian Cancer
University of MiamiP4B (62)
Trabectedin
Ovarian Cancer
Grupo Español de Investigación en Cáncer de OvarioP4B (62)
Epirubicin
Ovarian Cancer
Kalinski, Pawel, MD, PhDP3B (62)
FLUOROURACILUM
Ovarian Cancer
Lipomedix Pharmaceuticals Inc.P2B (62)
PEGFILGRASTIM
Ovarian Cancer
University of California, IrvineP4B (61)
Atezolizumab
Ovarian Cancer
OHSU Knight Cancer InstituteP3B (61)
Mirvetuximab Soravtansine
Ovarian Cancer
AbbVieP3B (61)
Showing 1 to 25 of 440 assets
PreviousPage 1 of 18Next